![Bastian Dehmel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bastian Dehmel
Corporate Officer/Principal presso OCULIS HOLDING AG
Posizioni attive di Bastian Dehmel
Società | Posizione | Inizio | Fine |
---|---|---|---|
OCULIS HOLDING AG | Corporate Officer/Principal | 01/01/2022 | - |
Storia della carriera di Bastian Dehmel
Precedenti posizioni note di Bastian Dehmel
Società | Posizione | Inizio | Fine |
---|---|---|---|
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Direttore Tecnico/Scientifico/R&S | 01/10/2017 | 01/12/2021 |
Amgen (Europe) GmbH | Corporate Officer/Principal | 01/12/2013 | 01/07/2017 |
Formazione di Bastian Dehmel
Freie Universität Berlin | Doctorate Degree |
Statistiche
Distribuzione geografica
Svizzera | 3 |
Svezia | 2 |
Germania | 2 |
Posizioni
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
OCULIS HOLDING AG | Health Technology |
Aziende private | 2 |
---|---|
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
Amgen (Europe) GmbH |
- Borsa valori
- Insiders
- Bastian Dehmel
- Esperienza